BioPharmSignal logoBioPharmSignal

Biotech News

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

Sarepta Therapeutics (SRPT)Sarepta TherapeuticsCompany update

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 1, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47 th Annual Global

Related news

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-07-29 21:00 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRSPCRISPR Therapeutics2026-05-28 12:00 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

NTLAIntellia2026-05-05 11:30 EST

Intellia Therapeutics to Participate in Upcoming Investor Conferences

OCGNOcugen2026-07-31 11:02 EST

Ocugen to Participate in Upcoming August Investor Conferences

OCGNOcugen2026-06-02 11:03 EST

Ocugen to Participate in Upcoming June Investor and Industry Conferences

RCKTRocket Pharmaceuticals2026-05-28 11:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

ABEOAbeona Therapeutics2026-05-26 12:30 EST

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

SANASana Biotechnology2026-05-27 20:05 EST

Sana Biotechnology to Present at June 2026 Investor Conferences

CRBUCaribou2026-05-13 20:05 EST

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

View all latest news

Sarepta Therapeutics

Precision Genetic Medicine Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy. ELEVIDYS ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients...

Recent company news

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-07-29 21:00 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRPTSarepta Therapeutics2026-07-27 12:30 EST

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

SRPTSarepta Therapeutics2026-07-22 12:30 EST

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

SRPTSarepta Therapeutics2026-06-30 20:25 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
16.78 USD
Market cap
1.72B USD
Exchange
NASDAQ
Sector
Gene Therapy
Location
United States